Davis Polk advised the joint book-running managers in connection with the $120 million follow-on offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock is listed on The NASDAQ Global Select Market under the symbol “GBT.”
Based in South San Francisco, California, Global Blood is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, including sickle cell disease.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender, Amy Tu and Randy Li. The tax team included partner Rachel D. Kleinberg and associate Lena X. Qiu. The intellectual property and technology team included partner Pritesh P. Shah and associate Paul S. Lee. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.